Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the promising stocks to buy under $50. On January 8, Morgan Stanley analyst Maxwell Skor lowered the firm’s price target on Ultragenyx to $50 from $55 and kept an Overweight rating on the shares. The firm projects continued outperformance for US SMID-cap biotech in 2026. This bullish outlook is driven by commercial-stage companies transitioning from capital consumers to producers, combined with a looming patent cliff that threatens the revenue of large ...